文献速递银屑病与炎症性皮肤病

乌帕替尼治疗掌跖脓疱病:开放标签、评估者盲法可行性研究

Upadacitinib for Palmoplantar Pustulosis: An Open-label, Assessor-blinded Feasibility Study Using Historic Control Data (JAKPPPOT).
PubMed 文献 · Br J Dermatol · 2026-09-26

这项在英国国家专科皮肤科中心开展的开放标签、评估者盲法可行性试验纳入20例中重度掌跖脓疱病患者,给予乌帕替尼30 mg每日一次治疗8周。研究达到全部预设可行性指标,且第8周基线校正后PP-PASI较历史安慰剂组改善-12.3(95%CI -15.8至-8.9),支持开展多中心阳性对照随机对照试验。

要点

  • 招募同意率41.8%、依从率95%、可接受度94.7%,全部预设可行性标准达标
  • 第8周基线校正后PP-PASI较历史安慰剂改善-12.3(95%CI -15.8至-8.9)
  • 常见不良事件为头痛、痤疮和上呼吸道感染

核心结论

  • 在掌跖脓疱病中开展JAK抑制剂随机对照试验是可行的,乌帕替尼显示出鼓舞性的探索性疗效信号。
  • 研究结果支持推进至多中心、阳性对照的随机对照试验。

研究设计与样本

  • 开放标签、评估者盲法的可行性试验,在英国国家专科皮肤科中心开展。
  • 纳入≥18岁中重度掌跖脓疱病成人,乌帕替尼30 mg每日一次治疗8周,高风险个体用15 mg。
  • 与既往掌跖脓疱病随机对照试验流程协调,以便与历史安慰剂数据比较。
  • 分析为描述性,基线校正PP-PASI变化用线性(高斯)混合效应模型估计。

主要发现

  • 67名被联系者中28人同意(41.8%),20人开始治疗(71.4%);平均年龄46.0岁,85%为女性。
  • 19/20例(95%)达到依从≥80%,平均覆盖天数比例95.7%(SD 9.7);18/19例(94.7%)认为治疗可接受。
  • 乌帕替尼组平均PP-PASI由基线20.3(SD 10.6)降至第8周4.6(SD 4.5);历史安慰剂组由18.0(SD 10.4)降至15.4(SD 10.1)。
  • 第8周乌帕替尼相对历史安慰剂的基线校正PP-PASI变化为-12.3(95%CI -15.8至-8.9),利于乌帕替尼。
  • 乌帕替尼相对历史安慰剂的PP-PASI50为100% vs 16.1%,PP-PASI75为65.0% vs 3.2%。

关键数值与推荐

  • 可行性主要终点:招募(同意率)、依从(≥80%天数覆盖)、可接受度(治疗后5点Likert量表评为「完全可接受」或「可接受」)。
  • 全部预设可行性标准均达到。
  • 次要结局包括PP-PASI自基线的变化与安全性。

临床怎么用

  • 结果提示乌帕替尼在掌跖脓疱病中可能有效且可耐受,但属探索性证据,尚不足以直接改变常规处方。
  • 可行性数据可用于设计多中心、JAK抑制剂与活性对照药的随机对照试验。

局限性

  • 开放标签设计,无同期安慰剂对照,疗效比较依赖历史安慰剂数据。
  • 样本量小(20例开始治疗),可行性结论外推需谨慎。
  • 单中心开展,治疗时长仅8周,长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palmoplantar pustulosis (PPP) is a rare, disabling inflammatory skin disease with substantial unmet need. Janus kinase inhibitors (JAKi) target inflammatory pathways implicated in PPP. High smoking prevalence and rare disease status mean that a randomised controlled trial (RCT) to evaluate the efficacy and safety of JAKi in PPP may be challenging. OBJECTIVES: To determine the feasibility of a future RCT of JAKi therapy in PPP and generate an exploratory estimate of treatment effect. METHODS: This open-label, assessor-blinded feasibility trial, conducted at a UK national specialist dermatology centre, enrolled adults (≥18 years) with moderate-to-severe PPP and treated them with upadacitinib 30 mg once daily for 8 weeks (15 mg for higher-risk individuals). Primary feasibility endpoints were recruitment (consent rate), adherence (≥80% of days covered), and acceptability ('completely acceptable'/'acceptable' on post-treatment 5-point Likert scale). Secondary outcomes included change from baseline in Palmoplantar Pustulosis-Psoriasis Area and Severity Index (PP-PASI) and safety. Study procedures were harmonised with a previous RCT in PPP, permitting comparison with historic placebo data. Analyses were descriptive with baseline-adjusted PP-PASI change estimated with a linear (Gaussian) mixed-effects model. RESULTS: All prespecified feasibility criteria were met. Of 67 contacted individuals, 28 consented (41.8%), and 20 started treatment (71.4%; mean age 46.0 years; 85% female). Adherence ≥80% was achieved by 19/20 participants (95%), with a mean proportion of days covered of 95.7% (SD 9.7). 18/19 participants (94.7%) viewed treatment as acceptable. Mean PP-PASI decreased from 20.3 (SD 10.6) at baseline to 4.6 (SD 4.5) at week 8 with upadacitinib, versus 18.0 (SD 10.4) to 15.4 (SD 10.1) with historic placebo. Baseline-adjusted PP-PASI change at week 8 for upadacitinib relative to historic placebo was -12.3 (95% CI -15.8 to -8.9) in favour of upadacitinib. PP-PASI50 and PP-PASI75 responses with upadacitinib relative to historic placebo were 100% vs 16.1% and 65.0% vs 3.2%. The most common adverse events were headache, acne, and upper respiratory tract infections. CONCLUSIONS: This study demonstrates that a definitive trial of JAK inhibition in PPP is feasible and identifies an encouraging exploratory efficacy signal. The findings support progression to a multicentre active-comparator randomised controlled trial.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gleeson D, Chapman S, Qin N, et al. Upadacitinib for Palmoplantar Pustulosis: An Open-label, Assessor-blinded Feasibility Study Using Historic Control Data (JAKPPPOT). Br J Dermatol. 2026. PMID: 42791196. doi:10.1093/bjd/ljag410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。